ヒト抗菌薬感受性試験市場：タイプ、製品、方法、用途、エンドユーザー別-2025-2030年世界予測

ヒト抗菌薬感受性試験市場は、2023年に37億1,000万米ドルと評価され、2024年には39億2,000万米ドルに達すると予測され、CAGR 5.88％で成長し、2030年には55億4,000万米ドルに達すると予測されています。

ヒト抗菌薬感受性試験市場は、感染症の正確な治療と管理を保証するために、特定の抗菌剤に対する感受性を決定するために病原体を評価することを含みます。この検査は、抗菌薬耐性（AMR）の脅威の高まりに対抗し、臨床現場における十分な情報に基づいた意思決定を促進し、精密医療を導き、新規抗生物質開発における製薬研究を支援するために不可欠です。主な用途には病院、診断センター、研究所などがあり、エンドユーザーはヘルスケアプロバイダーから製薬企業まで多岐にわたる。市場成長の大きな原動力となっているのは、感染症の流行の増加、迅速な診断技術の必要性、AMRに対する意識の高まりです。自動化システムや分子診断ツールなどの技術的進歩は、市場拡大の大きなチャンスです。しかし、高度な検査技術に関連する高コスト、低所得地域でのアクセス制限、標準化された検査プロトコルの開発の複雑さなどの要因が市場開拓を妨げています。成長機会を生かすために、企業は費用対効果の高い迅速診断技術の開発に投資し、パートナーシップを拡大して発展途上国での市場浸透を図るべきです。AIと機械学習を抗菌薬感受性検査に統合し、予測精度と効率を高めることには貴重な機会があります。さらに、個別化医療に向けた動向の高まりは、オーダーメイドの抗菌薬ソリューションを開発する道を提供します。課題としては、規制上のハードルや、進化する耐性菌に対応するための継続的な技術革新の必要性などが挙げられます。企業はまた、潜在的な市場参入障壁を回避するために、規制状況の変化を予測し、それに適応する必要があります。ポイント・オブ・ケア検査と検査精度の向上に焦点を当てたイノベーションは、事業成長の大きな可能性を提供します。市場は急速な技術進歩と厳しい規制環境を特徴とするダイナミックな市場であるため、企業が競争力を維持し長期的な成功を収めるためには、継続的な研究開発と戦略的提携が不可欠となります。

市場力学：急速に進化するヒト抗菌薬感受性試験市場の主要市場インサイトを公開

ヒト抗菌薬感受性試験市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 病原体の増加による感染症の流行増加
  • 抗菌剤耐性に対する認識を高め、抗菌剤の乱用を抑制するための政府イニシアチブの高まり
  • バイオ医薬品企業による抗菌薬感受性試験の利用急増
• 市場抑制要因
  • 自動化された抗菌薬感受性試験の高コスト
• 市場機会
  • 迅速なヒトAST法の開発に向けた技術の進歩
  • 市場への資金提供、研究助成金、官民投資の増加
• 市場の課題
  • 複雑な規制の枠組みと発展途上国における検査の問題点

ポーターのファイブフォース：ヒト抗菌薬感受性試験市場をナビゲートする戦略ツール

ポーターのファイブフォース（5つの力）は、市場情勢の競合情勢を把握するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：ヒト抗菌薬感受性試験市場における外部からの影響の把握

外部マクロ環境要因は、ヒト抗菌薬感受性試験市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析ヒト抗菌薬感受性試験市場における競合情勢の把握

ヒト抗菌薬感受性試験市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスヒト抗菌薬感受性試験市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、ヒト抗菌薬感受性試験市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨ヒト抗菌薬感受性試験市場における成功への道筋を描く

ヒト抗菌薬感受性試験市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大の可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 病原体の増加による感染症の蔓延の増加
    • 抗菌薬耐性に関する意識を高め、抗菌薬乱用を抑制するための政府の取り組みが増加
    • バイオ医薬品企業による抗菌薬感受性試験の利用が急増
  • 抑制要因
    • 自動化された抗菌薬感受性検査の高コスト
  • 機会
    • 迅速なヒトAST検査法の開発に向けた技術的進歩
    • 市場への資金、調査助成金、官民投資の増加
  • 課題
    • 複雑な規制枠組みと新興諸国における検査の問題
• 市場セグメンテーション分析
  • タイプ：次世代感受性試験の開発に向けた研究開発投資の増加
  • エンドユーザー：患者固有の治療戦略を指導するための病院および診断センターでの需要の高まり
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 ヒト抗菌薬感受性試験市場：タイプ別

• 抗菌薬感受性試験
• 抗真菌薬感受性試験
• 抗寄生虫感受性試験

第7章 ヒト抗菌薬感受性試験市場：製品別

• 自動化された実験装置
• 消耗品
• 文化と成長メディア
• 手動抗菌薬感受性試験製品

第8章 ヒト抗菌薬感受性試験市場：方法別

• 寒天希釈液
• 自動感受性試験装置
• ディスク拡散
• Eテスト方法
• ジェノタイピング法

第9章 ヒト抗菌薬感受性試験市場：用途別

• 臨床診断
• 医薬品の発見と開発
• 疫学

第10章 ヒト抗菌薬感受性試験市場：エンドユーザー別

• 契約調査機関
• 病院および診断センター
• 製薬・バイオテクノロジー
• 調査・学術機関

第11章 南北アメリカのヒト抗菌薬感受性試験市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域のヒト抗菌薬感受性試験市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカのヒト抗菌薬感受性試験市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • CARB-Xによる抗生物質耐性淋病の撲滅と世界の性感染症管理の強化に向けた迅速診断技術への戦略的投資
  • マイクロプレート社、抗菌薬耐性と闘うためのイノベーションのための資金を確保
  • シスメックスの迅速抗菌薬感受性検査システムの紹介
• 戦略分析と提言

企業一覧

• Alifax S.r.l.
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• BIOANALYSE TIBBI MALZ
• BioMerieux SA
• Biosafe Ltd.
• Bruker Corporation
• Creative Diagnostics
• ELITech Group SAS
• Erba Lachema s.r.o.
• F. Hoffmann-La Roche AG
• Genefluidics, Inc.
• Himedia Laboratories Private Limited
• INTEGRA Biosciences AG
• Laboratorios Conda, S.A.
• Launch Diagnostics Limited
• Liofilchem S.r.l.
• Mast Group Ltd.
• Merck KGaA
• Pfizer Inc.
• Thermo Fisher Scientific Inc.
• Zhuhai DL Biotech Co., Ltd.

LIST OF FIGURES

• FIGURE 1. HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET RESEARCH PROCESS
• FIGURE 2. HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET DYNAMICS
• TABLE 7. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBACTERIAL SUSCEPTIBILITY TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIFUNGAL SUSCEPTIBILITY TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIPARASITIC SUSCEPTIBILITY TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED LABORATORY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CULTURE & GROWTH MEDIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SUSCEPTIBILITY TESTING INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ETEST METHOD, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GENOTYPING METHODS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITAL & DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 47. CANADA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 48. CANADA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 49. CANADA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 50. CANADA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 51. CANADA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 55. MEXICO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 56. MEXICO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 61. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 62. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 66. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 67. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 68. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. AUSTRALIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 71. AUSTRALIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 72. AUSTRALIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 73. AUSTRALIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 74. CHINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 75. CHINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 76. CHINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 77. CHINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 78. CHINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 79. INDIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. INDIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 81. INDIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 82. INDIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 83. INDIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 85. INDONESIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 86. INDONESIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 87. INDONESIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 88. INDONESIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. JAPAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 91. JAPAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 92. JAPAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 93. JAPAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. MALAYSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 96. MALAYSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 97. MALAYSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. MALAYSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 100. PHILIPPINES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 101. PHILIPPINES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 102. PHILIPPINES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 103. PHILIPPINES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 105. SINGAPORE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 106. SINGAPORE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 107. SINGAPORE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 108. SINGAPORE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. SOUTH KOREA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 111. SOUTH KOREA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 112. SOUTH KOREA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. SOUTH KOREA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 115. TAIWAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 116. TAIWAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 117. TAIWAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 118. TAIWAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 120. THAILAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 121. THAILAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 122. THAILAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 123. THAILAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. VIETNAM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 126. VIETNAM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 127. VIETNAM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 128. VIETNAM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 132. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 134. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 136. DENMARK HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 137. DENMARK HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 138. DENMARK HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 139. DENMARK HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 141. EGYPT HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 142. EGYPT HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 143. EGYPT HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 144. EGYPT HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 146. FINLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 147. FINLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 148. FINLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 149. FINLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 151. FRANCE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 152. FRANCE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 153. FRANCE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 154. FRANCE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 156. GERMANY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 157. GERMANY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 158. GERMANY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 159. GERMANY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 161. ISRAEL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 162. ISRAEL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 163. ISRAEL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 164. ISRAEL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 165. ITALY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 166. ITALY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 167. ITALY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 168. ITALY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 169. ITALY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 171. NETHERLANDS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 172. NETHERLANDS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 173. NETHERLANDS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 174. NETHERLANDS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 176. NIGERIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 177. NIGERIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 178. NIGERIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 179. NIGERIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 181. NORWAY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 182. NORWAY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 183. NORWAY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 184. NORWAY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 185. POLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 186. POLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 187. POLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 188. POLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 189. POLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 190. QATAR HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 191. QATAR HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 192. QATAR HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 193. QATAR HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 194. QATAR HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 196. RUSSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 197. RUSSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 198. RUSSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 199. RUSSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 201. SAUDI ARABIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 202. SAUDI ARABIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 203. SAUDI ARABIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 204. SAUDI ARABIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 208. SOUTH AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 209. SOUTH AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 211. SPAIN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 212. SPAIN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 213. SPAIN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 214. SPAIN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 216. SWEDEN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 217. SWEDEN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 218. SWEDEN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 219. SWEDEN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 221. SWITZERLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 222. SWITZERLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 223. SWITZERLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 224. SWITZERLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 226. TURKEY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 227. TURKEY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 228. TURKEY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 229. TURKEY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 231. UNITED ARAB EMIRATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 232. UNITED ARAB EMIRATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 233. UNITED ARAB EMIRATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 234. UNITED ARAB EMIRATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 236. UNITED KINGDOM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 237. UNITED KINGDOM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 238. UNITED KINGDOM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 239. UNITED KINGDOM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 240. HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 241. HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, FPNV POSITIONING MATRIX, 2023

The Human Antimicrobial Susceptibility Testing Market was valued at USD 3.71 billion in 2023, expected to reach USD 3.92 billion in 2024, and is projected to grow at a CAGR of 5.88%, to USD 5.54 billion by 2030.

The human antimicrobial susceptibility testing market involves the evaluation of pathogens to determine their susceptibility to specific antimicrobial agents, ensuring accurate treatment and management of infections. This testing is essential in combating the rising threat of antimicrobial resistance (AMR), facilitating informed decisions in clinical settings, guiding precision medicine, and aiding pharmaceutical research in novel antibiotic development. Key applications include hospitals, diagnostic centers, and research laboratories, while end-users range from healthcare providers to pharmaceutical firms. Market growth is significantly driven by the increasing prevalence of infectious diseases, the need for rapid diagnostic techniques, and a rising awareness of AMR. Technological advancements, such as automated systems and molecular diagnostic tools, present substantial opportunities for enhancement. However, market growth is hindered by factors like the high costs associated with advanced testing technologies, limited access in low-income regions, and the complexity of developing standardized testing protocols. To capitalize on growth opportunities, firms should invest in developing cost-effective and rapid diagnostic technologies, and expand partnerships to increase market penetration in developing nations. There's a valuable opportunity in integrating AI and machine learning into antimicrobial susceptibility testing to enhance predictive accuracy and efficiency. Moreover, the growing trend towards personalized medicine offers avenues for developing tailored antimicrobial solutions. Challenging factors include regulatory hurdles and the need for continual innovation to keep pace with evolving bacterial resistance. Firms should also anticipate and adapt to changes in the regulatory landscape to avoid potential market entry barriers. Innovations focusing on point-of-care testing and enhancing testing accuracy offer significant potential for business growth. As the market is dynamic, characterized by rapid technological advancements and stringent regulatory environments, continuous R&D and strategic partnerships will be crucial for businesses to maintain a competitive edge and drive long-term success.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Human Antimicrobial Susceptibility Testing Market

The Human Antimicrobial Susceptibility Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of infectious diseases due to the rising pathogens
  • Rising government initiatives to create awareness of antimicrobial resistance and curb antimicrobial abuse
  • Surging use of antimicrobial susceptibility testing by biopharmaceutical companies
• Market Restraints
  • High cost of automated antimicrobial susceptibility testing
• Market Opportunities
  • Technological advancements towards the development of rapid human AST methods
  • Increasing funding, research grants, and public-private investments in the market
• Market Challenges
  • Complex regulatory frameworks coupled with issues in testing in developing countries

Porter's Five Forces: A Strategic Tool for Navigating the Human Antimicrobial Susceptibility Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Human Antimicrobial Susceptibility Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Human Antimicrobial Susceptibility Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Human Antimicrobial Susceptibility Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Human Antimicrobial Susceptibility Testing Market

A detailed market share analysis in the Human Antimicrobial Susceptibility Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Human Antimicrobial Susceptibility Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Human Antimicrobial Susceptibility Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Human Antimicrobial Susceptibility Testing Market

A strategic analysis of the Human Antimicrobial Susceptibility Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Human Antimicrobial Susceptibility Testing Market, highlighting leading vendors and their innovative profiles. These include Alifax S.r.l., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BIOANALYSE TIBBI MALZ, BioMerieux SA, Biosafe Ltd., Bruker Corporation, Creative Diagnostics, ELITech Group SAS, Erba Lachema s.r.o., F. Hoffmann-La Roche AG, Genefluidics, Inc., Himedia Laboratories Private Limited, INTEGRA Biosciences AG, Laboratorios Conda, S.A., Launch Diagnostics Limited, Liofilchem S.r.l., Mast Group Ltd., Merck KGaA, Pfizer Inc., Thermo Fisher Scientific Inc., and Zhuhai DL Biotech Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Human Antimicrobial Susceptibility Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Antibacterial Susceptibility Testing, Antifungal Susceptibility Testing, and Antiparasitic Susceptibility Testing.
• Based on Product, market is studied across Automated Laboratory Instruments, Consumables, Culture & Growth Media, and Manual Antimicrobial Susceptibility Testing Products.
• Based on Method, market is studied across Agar Dilution, Automated Susceptibility Testing Instruments, Disk Diffusion, Etest Method, and Genotyping Methods.
• Based on Application, market is studied across Clinical Diagnostics, Drug Discovery & Development, and Epidemiology.
• Based on End User, market is studied across Contract Research Organizations, Hospital & Diagnostic Centers, Pharmaceutical & Biotechnology, and Research & Academic Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of infectious diseases due to the rising pathogens
    • 5.1.1.2. Rising government initiatives to create awareness of antimicrobial resistance and curb antimicrobial abuse
    • 5.1.1.3. Surging use of antimicrobial susceptibility testing by biopharmaceutical companies
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of automated antimicrobial susceptibility testing
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements towards the development of rapid human AST methods
    • 5.1.3.2. Increasing funding, research grants, and public-private investments in the market
  • 5.1.4. Challenges
    • 5.1.4.1. Complex regulatory frameworks coupled with issues in testing in developing countries
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Rising R&D investment to develop next generation susceptibility testing
  • 5.2.2. End User: Rising demand across hospital & diagnostic centers to guide patient-specific treatment strategies
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Human Antimicrobial Susceptibility Testing Market, by Type

• 6.1. Introduction
• 6.2. Antibacterial Susceptibility Testing
• 6.3. Antifungal Susceptibility Testing
• 6.4. Antiparasitic Susceptibility Testing

7. Human Antimicrobial Susceptibility Testing Market, by Product

• 7.1. Introduction
• 7.2. Automated Laboratory Instruments
• 7.3. Consumables
• 7.4. Culture & Growth Media
• 7.5. Manual Antimicrobial Susceptibility Testing Products

8. Human Antimicrobial Susceptibility Testing Market, by Method

• 8.1. Introduction
• 8.2. Agar Dilution
• 8.3. Automated Susceptibility Testing Instruments
• 8.4. Disk Diffusion
• 8.5. Etest Method
• 8.6. Genotyping Methods

9. Human Antimicrobial Susceptibility Testing Market, by Application

• 9.1. Introduction
• 9.2. Clinical Diagnostics
• 9.3. Drug Discovery & Development
• 9.4. Epidemiology

10. Human Antimicrobial Susceptibility Testing Market, by End User

• 10.1. Introduction
• 10.2. Contract Research Organizations
• 10.3. Hospital & Diagnostic Centers
• 10.4. Pharmaceutical & Biotechnology
• 10.5. Research & Academic Institutes

11. Americas Human Antimicrobial Susceptibility Testing Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Human Antimicrobial Susceptibility Testing Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Human Antimicrobial Susceptibility Testing Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Strategic Investment in Rapid Diagnostic Technologies by CARB-X to Combat Antibiotic-Resistant Gonorrhea and Enhance Global STI Management
  • 14.3.2. Microplate Secures Funding for Innovation in Combatting Antimicrobial Resistance
  • 14.3.3. Introducing Sysmex's Rapid Antimicrobial Susceptibility Testing System
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Alifax S.r.l.
• 2. Becton, Dickinson and Company
• 3. Bio-Rad Laboratories, Inc.
• 4. BIOANALYSE TIBBI MALZ
• 5. BioMerieux SA
• 6. Biosafe Ltd.
• 7. Bruker Corporation
• 8. Creative Diagnostics
• 9. ELITech Group SAS
• 10. Erba Lachema s.r.o.
• 11. F. Hoffmann-La Roche AG
• 12. Genefluidics, Inc.
• 13. Himedia Laboratories Private Limited
• 14. INTEGRA Biosciences AG
• 15. Laboratorios Conda, S.A.
• 16. Launch Diagnostics Limited
• 17. Liofilchem S.r.l.
• 18. Mast Group Ltd.
• 19. Merck KGaA
• 20. Pfizer Inc.
• 21. Thermo Fisher Scientific Inc.
• 22. Zhuhai DL Biotech Co., Ltd.